PDGFRβ inhibitors(Platelet-derived growth factor receptor beta inhibitors), RET inhibitors(Tyrosine-protein kinase receptor RET inhibitors), Raf kinase inhibitors(RAF serine/threonine protein kinase inhibitors)

+ [1]

Therapeutic Areas

NeoplasmsDigestive System Disorders

Active Indication-

Inactive Indication

Advanced Malignant Solid NeoplasmLiver Cancer

Originator Organization

Guangzhou Nanxin Pharma Co Ltd

Active Organization-

Inactive Organization

Guangzhou Nanxin Pharma Co Ltd

Drug Highest PhasePendingPhase 1

First Approval Date-

Regulation-

Clinical Trials associated with Metarafenib

CTR20200257 / CompletedPhase 1

美他非尼片口服治疗中晚期原发性肝癌的多中心、开放Ib/IIa期临床研究

[Translation] A multicenter, open-label phase Ib/IIa clinical study of oral Metafenib tablets in the treatment of advanced primary liver cancer

主要目的：以疾病控制率（DCR）为指标，评估美他非尼片在中晚期原发性肝癌患者中的初步疗效次要目的：1.以疾病进展时间（TTP）、客观缓解率（ORR）、无进展生存期（PFS）、总生存期（OS）为指标，评估美他非尼片在中晚期原发性肝癌患者中的初步疗效、安全性、药代动力学特征

[Translation]

Primary objective: To evaluate the preliminary efficacy of tafenib tablets in patients with advanced primary liver cancer using disease control rate (DCR) as an indicator Secondary objectives: 1. To evaluate the preliminary efficacy, safety, and pharmacokinetic characteristics of tafenib tablets in patients with advanced primary liver cancer using time to disease progression (TTP), objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) as indicators

Start Date28 Apr 2020

Sponsor / Collaborator

Guangzhou Nanxin Pharma Co Ltd

CTR20171556 / CompletedPhase 1

美他非尼片治疗晚期实体瘤患者单中心、开放、剂量递增的耐受、PK I期临床试验

[Translation] A single-center, open-label, dose-escalation, phase I clinical trial of metafenib tablets in patients with advanced solid tumors

主要目的：观察美他非尼片在晚期实体瘤患者中单次给药及连续给药28天的安全和耐受性，探索最大耐受剂量（MTD）次要目的：考察美他非尼片在晚期实体瘤患者中单次给药及连续给药28天的PK参数；观察美他非尼片治疗晚期实体瘤患者的疾病控制率（DCR）及无进展生存期（PFS），初步评价美他非尼片的抗肿瘤疗效。

[Translation]

Primary objective: To observe the safety and tolerability of single administration and continuous administration for 28 days of Metafenib tablets in patients with advanced solid tumors, and to explore the maximum tolerated dose (MTD). Secondary objective: To investigate the PK parameters of single administration and continuous administration for 28 days of Metafenib tablets in patients with advanced solid tumors; To observe the disease control rate (DCR) and progression-free survival (PFS) of Metafenib tablets in the treatment of patients with advanced solid tumors, and to preliminarily evaluate the anti-tumor efficacy of Metafenib tablets.

Start Date27 Dec 2017

Sponsor / Collaborator

Guangzhou Nanxin Pharma Co Ltd

100 Clinical Results associated with Metarafenib

100 Translational Medicine associated with Metarafenib

100 Patents (Medical) associated with Metarafenib

100 Deals associated with Metarafenib

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Liver Cancer	Phase 1	CN	Guangzhou Nanxin Pharma Co Ltd	28 Apr 2020
Advanced Malignant Solid Neoplasm	Phase 1	CN	Guangzhou Nanxin Pharma Co Ltd	27 Dec 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Metarafenib

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation